• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 5:02:15 PM ET
    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENDP alert in real time by email
    SC 13G 1 endp13g-021621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. )1
     
    Endo International plc
    (Name of Issuer)
    Ordinary Shares, $0.0001 nominal value per share
    (Title of Class of Securities)
    G30401106
    (CUSIP Number)
    September 30, 2020
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     ☐
    Rule 13d-1(b)
     
     ☒
    Rule 13d-1(c)
     
     ☐
    Rule 13d-1(d)
     
     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    PAULSON & CO. INC.
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☒
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    18,327,012 (See Note 1 to Item 4 below)
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    0
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    18,327,012 (See Note 1 to Item 4 below)
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    0
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    18,327,012 (See Note 1 to Item 4 below)
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    8.0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IA
     
     



     
    Item 1(a).
    Name of Issuer:
     
    Endo International plc
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland
     
    Item 2(a).
    Name of Persons Filing:

    Paulson & Co. Inc. (the “Reporting Person”)
     
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    1133 Avenue of the Americas, New York, NY 10036
     
    Item 2(c).
    Citizenship:

    Delaware corporation
     
    Item 2(d).
    Title of Class of Securities:

    Ordinary shares, $0.0001 par value per share (the “Ordinary Shares”)
     
    Item 2(e).
    CUSIP Number:

    G30401106
     
    Item 3.
    If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    /x/
    Not Applicable
    (a)
    / /
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)
    / /
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    / /
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    / /
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    / /
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).*
    (f)
    / /
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
    (g)
    / /
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).**
    (h)
    / /
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    / /
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
    (j)
    / /
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
    (k)
    / /
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).



     
    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer.

    (a)
    Amount beneficially owned: 18,327,012

    (b)
    Percent of class: 8.0%
    (c)            Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote: 18,327,012 (See Note 1)

     (ii)
    Shared power to vote or to direct the vote: 0

     (iii)
    Sole power to dispose or to direct the disposition of: 18,327,012 (See Note 1)

     (iv)
    Shared power to dispose or to direct the disposition of: 0
    The aggregate percentage of Ordinary Shares reported owned by each person named herein is based upon 230,292,329 Ordinary Shares outstanding as of October 30, 2020, which is the total number of Ordinary Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.
    Note 1: Paulson & Co. Inc. (“Paulson”) and its affiliates furnish investment advice to and manage onshore and offshore investment funds and separate managed accounts (such investment funds and accounts, the “Funds”).  In its role as investment advisor, or manager, Paulson possesses voting and/or investment power over the securities of the Issuer described in this schedule that are owned by the Funds.  All securities reported in this schedule are owned by the Funds.  Paulson disclaims beneficial ownership of such securities.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.

    Not applicable.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    All securities reported in this schedule are owned by Paulson's advisory clients, none of which to Paulson's knowledge owns more than 5% of the class. Paulson itself disclaims beneficial ownership of all such securities.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.


     
    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
     
    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.



    SIGNATURES
    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information with respect to it or him set forth in this statement is true, complete and correct.
    Dated:  February 16, 2021
    PAULSON & CO. INC.
    By: /s/ Stuart L. Merzer 
          Stuart L. Merzer,
          General Counsel & Chief Compliance Officer
    Get the next $ENDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENDP

    DatePrice TargetRatingAnalyst
    5/6/2022$3.00 → $1.00Neutral → Underweight
    Piper Sandler
    3/9/2022$11.00 → $6.00Buy
    Citigroup
    3/2/2022$5.00 → $3.00Neutral
    Piper Sandler
    3/2/2022$5.00 → $2.00Equal-Weight → Underweight
    Barclays
    12/16/2021$7.00 → $5.00Equal-Weight
    Barclays
    8/31/2021$10.00 → $3.00Overweight → Neutral
    Piper Sandler
    8/9/2021$6.00 → $5.00Sector Perform
    RBC Capital
    More analyst ratings

    $ENDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Endo International plc

      SC 13G - Endo International plc (0001593034) (Subject)

      9/8/22 1:43:40 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Endo International plc

      SC 13G - Endo International plc (0001593034) (Subject)

      8/29/22 4:05:14 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Endo International plc

      SC 13G - Endo International plc (0001593034) (Subject)

      7/8/22 4:56:55 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Endo Intl downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Endo Intl from Neutral to Underweight and set a new price target of $1.00 from $3.00 previously

      5/6/22 12:33:04 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Endo International with a new price target

      Citigroup reiterated coverage of Endo International with a rating of Buy and set a new price target of $6.00 from $11.00 previously

      3/9/22 7:39:21 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Endo International with a new price target

      Piper Sandler reiterated coverage of Endo International with a rating of Neutral and set a new price target of $3.00 from $5.00 previously

      3/2/22 8:48:56 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENDP
    Financials

    Live finance-specific insights

    See more

    $ENDP
    SEC Filings

    See more

    $ENDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ENDP
    Leadership Updates

    Live Leadership Updates

    See more

    $ENDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

      DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer. "As we manage thro

      5/5/22 4:30:00 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

      DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durabl

      5/2/22 7:55:00 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo to Announce First-Quarter 2022 Financial Results

      DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from May 6, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on May

      4/12/22 5:00:00 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo International plc filed SEC Form 8-K: Other Events

      8-K - Endo International plc (0001593034) (Filer)

      1/24/23 9:15:55 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo International plc filed SEC Form 8-K: Other Events

      8-K - Endo International plc (0001593034) (Filer)

      12/30/22 9:09:01 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Endo International plc (0001593034) (Filer)

      12/22/22 4:23:57 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

      MONTREAL, June 12, 2023 /CNW/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sensitivit

      6/12/23 7:39:54 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

      MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sen

      6/12/23 7:39:49 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

      Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebted

      8/16/22 10:00:00 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

      DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022.  He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. "Dr. Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. "His broad therapeutic expertis

      1/11/22 7:00:00 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Endo Appoints Jennifer M. Chao to Board of Directors

      DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately.  Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board.  Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Continue Reading Jennifer M. Chao Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy.  She is the founder

      2/17/21 4:15:00 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma Announces New Board Appointments

      Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Kn

      12/9/20 7:00:00 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tursi James Patrick returned 280,373 units of 2015 Stock Incentive Plan Restricted Stock Units to the company, closing all direct ownership in the company

      4 - Endo International plc (0001593034) (Issuer)

      8/17/22 6:31:28 AM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Barry Patrick A converted options into 16,957 units of Ordinary Shares and covered exercise/tax liability with 9,116 units of Ordinary Shares, increasing direct ownership by 5% to 169,711 units (withholding tax)

      4 - Endo International plc (0001593034) (Issuer)

      3/31/22 4:09:54 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Raciti Frank B. covered exercise/tax liability with 965 units of Ordinary Shares, decreasing direct ownership by 10% to 8,821 units to cover taxes

      4 - Endo International plc (0001593034) (Issuer)

      3/31/22 4:08:17 PM ET
      $ENDP
      Biotechnology: Pharmaceutical Preparations
      Health Care